⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRSN News
NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
prnewswire.com
NRSN
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
prnewswire.com
NRSN
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
prnewswire.com
NRSN
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
prnewswire.com
NRSN
IONQ
MNOV
CLNN
RVSN
BIIB
ABSI
CLNE
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
prnewswire.com
NRSN
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
prnewswire.com
NRSN
NeuroSense to Host Investor Webinar on December 8, 2025
prnewswire.com
NRSN
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
prnewswire.com
NRSN
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
prnewswire.com
NRSN